Ultragenyx Pharmaceutical RARE Institutional Ownership

Updated Oct 11, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) appeared in the 13F filings of 308 institutional investors for the quarter ended June 30, 2026.

• Total shares held in RARE rose 8.76% from Q1 2026; the number of holders rose 1.32% from Q2 2025.
• Of the 308 holders, 172 added to their positions, 98 reduced their stakes and 38 left their positions unchanged in Q2 2026.
• Institutional investors held 106.68Mn shares of Ultragenyx Pharmaceutical in total at the end of Q2 2026, up 8.6Mn from the prior quarter and up 13.33Mn from a year earlier.
• BlackRock, Inc. held the largest position in RARE at 10.65Mn shares as of June 30, 2026.
• The biggest increases in RARE positions during Q2 2026 came from RTW Investments, LP (+4.15Mn shares), BlackRock, Inc. (+3.35Mn shares), AQR Capital Management LLC (+1.98Mn shares), Jacobs Levy Equity Management, Inc (+1.51Mn shares) and Two Sigma Investments, LP (+1.42Mn shares).
• On the other side, among holders that kept a position in Ultragenyx Pharmaceutical, the largest reductions in Q2 2026 came from Assenagon Asset Management S.A. (-2.14Mn shares), Citadel Advisors LLC (-1.9Mn shares), Sofinnova Investments, Inc. (-1.43Mn shares), Wellington Management Group LLP (-1.39Mn shares) and Millennium Management LLC (-1.01Mn shares).
• Per Business Quant data, the 10 largest holders of Ultragenyx Pharmaceutical at the end of Q2 2026 were BlackRock, Inc. (10.65Mn shares), RTW Investments, LP (7.8Mn shares), Vanguard Portfolio Management LLC (6.79Mn shares), AQR Capital Management LLC (6.56Mn shares), State Street Corp (6.16Mn shares), Vanguard Capital Management LLC (4.3Mn shares), Two Sigma Investments, LP (3.62Mn shares), Sands Capital Management, LLC (3.16Mn shares), Jacobs Levy Equity Management, Inc (2.94Mn shares) and Frontier Capital Management Co LLC (2.85Mn shares).